The latest news about Montara

Montara Therapeutics, Inc., a preclinical-stage biotech company developing safer and more efficacious treatments for neurological diseases, today announced that founding investor and board member Dirk Landgraf, Ph.D., has transitioned from the company’s Board of Directors to its executive team as Chief Business Officer. Miles Gerson, Partner at SV Health Investors and co-leader of the Dementia Discovery Fund (DDF), has assumed SV’s seat on Montara’s Board. Both appointments come as Montara prepares to enter the clinic, having demonstrated proof of pharmacology in large-animal models with MTX-E1 and completed GLP safety studies of its first BrainOnly™ peripheral blocker.

Montara Therapeutics, a biotechnology company pioneering brain-selective therapies for CNS diseases, today announced the appointment of Andrew Miller, Ph.D., to its Board of Directors; the hiring of David Michelson, M.D., as Chief Medical Officer; and the promotion of Zachary Hill, Ph.D., to Chief Technology Officer.

Building on a prior MJFF-funded collaboration targeting LRRK2, Montara’s BrainOnly™ platform now targets the mTOR pathway — exploring a class of drugs with longstanding scientific interest but a history of safety challenges.

Montara’s BrainOnly platform is designed to prevent peripheral side effects and concentrate neurological drugs’ activity in the brain via two-drug combination therapies, comprising its non−brain-penetrant “universal” peripheral blocker development candidate, MT1110, and a brain-penetrant target-specific drug. Montara will enter the clinic in H2 2026 to study an MT1110-everolimus combination, called MTX-E1, for the treatment of TSC-related epilepsy and other mTOR-driven CNS diseases.